A5083284412- Systemic Lupus Erythematosus Research
- Biomedical Ethics and Regulation
- Atherosclerosis and Cardiovascular Diseases
- Prenatal Screening and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Virus-based gene therapy research
- Renal and related cancers
- Biological Research and Disease Studies
- Rheumatoid Arthritis Research and Therapies
- Inflammatory Bowel Disease
- Cystic Fibrosis Research Advances
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Potassium and Related Disorders
- Osteoarthritis Treatment and Mechanisms
- Pluripotent Stem Cells Research
- Vasculitis and related conditions
- Epilepsy research and treatment
- Gastroesophageal reflux and treatments
- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Renal Diseases and Glomerulopathies
- Health and Medical Research Impacts
- 3D Printing in Biomedical Research
- Monoclonal and Polyclonal Antibodies Research
- Circadian rhythm and melatonin
United States Food and Drug Administration
2008-2022
Center for Biologics Evaluation and Research
2018-2022
Boston Children's Hospital
2021
Harvard University
2021
Brigham and Women's Hospital
2021
KK Women's and Children's Hospital
2021
Duke-NUS Medical School
2021
Children's Hospital of Philadelphia
2021
Wake Forest University
2021
Forest Institute
2021
Abstract Objective To assess the association of cognitive dysfunction and depression with serum antibodies to N ‐methyl‐ D ‐aspartate (NMDA) receptor (anti‐NR2) analyze clinical neuroimaging correlates in patients systemic lupus erythematosus (SLE). Methods Sixty underwent neurocognitive assessment, evaluation for Beck Depression Inventory II (BDI‐II) psychiatric interview (Diagnostic Statistical Manual Mental Disorders, Fourth Edition [DSM‐IV] criteria), brain magnetic resonance imaging,...
Cognitive dysfunction and neuropsychiatric disturbance are common in systemic lupus erythematosus (SLE). This study addressed the ability of Automated Neuropsychological Assessment Metrics (ANAM), a computerized cognitive testing battery consisting subtests, sleepiness rating scale, mood to predict neuropsychological status patients with SLE.Sixty individuals SLE no overt symptoms were administered ANAM determine its validity as screening measure emotional distress SLE.Performance on was...
The Food and Drug Administration (FDA)'s Center for Evaluation Research (CDER) receives about 1500 initial Investigational New applications (INDs) per year. In the first 30 days after IND submission, FDA conducts a review to determine whether proposed investigation is safe proceed, if not, may be placed on clinical hold.A retrospective study of rates reasons hold all INDs submitted CDER in fiscal year (FY) 2013 was performed. were assessed that led hold, included chemistry, manufacturing...
ЖЕЛЕЗОДЕфИЦИТНЫЕ СОСТОЯНИЯ И ИНфЕКЦИЯHelicobActer pylori У ДЕТЕЙ Л. В. Лаптева ФГБНУ НИИ медицинских проблем Севера, Красноярск, врио директора -д.м. н., проф.С. В
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, International Society Nephrology held a Nexus meeting on Translational Immunology Berlin, Germany, to identify and discuss hurdles block translational flow target identification, preclinical clinical validation domain disease. A broad panel experts...
This article provides updates for several commonly used rheumatic disease treatments from the Office of New Drugs, Center Drug Development and Research, at United States Food Administration.